Page 21234..1020..»

Journey Medical Corporation Appoints Ernest De Paolantonio as Chief Financial Officer

By Dr. Matthew Watson

NEW YORK and SCOTTSDALE, Ariz., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”), a partner company of Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”) focused on identifying, acquiring, developing and strategically commercializing innovative, differentiated dermatology products, today announces the appointment of Ernest De Paolantonio as Chief Financial Officer, effective September 30, 2021.

Original post:
Journey Medical Corporation Appoints Ernest De Paolantonio as Chief Financial Officer

To Read More: Journey Medical Corporation Appoints Ernest De Paolantonio as Chief Financial Officer
categoriaGlobal News Feed commentoComments Off on Journey Medical Corporation Appoints Ernest De Paolantonio as Chief Financial Officer | dataOctober 5th, 2021
Read All

Skye Bioscience Appoints Kaitlyn Arsenault as Chief Financial Officer

By Dr. Matthew Watson

SAN DIEGO, CA, Oct. 05, 2021 (GLOBE NEWSWIRE) --  Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary cannabinoid-derived molecules to treat diseases with significant unmet need, has appointed Kaitlyn Arsenault, CPA, as Chief Financial Officer. Ms. Arsenault brings over 14 years of experience in accounting, auditing, financial reporting, mergers and acquisitions, as well as business operations in the life science and technology sectors.

See original here:
Skye Bioscience Appoints Kaitlyn Arsenault as Chief Financial Officer

To Read More: Skye Bioscience Appoints Kaitlyn Arsenault as Chief Financial Officer
categoriaGlobal News Feed commentoComments Off on Skye Bioscience Appoints Kaitlyn Arsenault as Chief Financial Officer | dataOctober 5th, 2021
Read All

Albireo Recognizes PFIC Awareness Day 2021

By Dr. Matthew Watson

BOSTON, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, joins the PFIC Advocacy and Resource Network (PFIC Network) in recognition of PFIC Awareness Day 2021, a global effort to support patients and families affected by progressive familial intrahepatic cholestasis (PFIC). Established in 2019, PFIC Awareness Day aims to highlight the impact of this disease on patients and families, and to call for new levels of support, including research, advocacy, education and opportunities to connect and share information.

See the original post here:
Albireo Recognizes PFIC Awareness Day 2021

To Read More: Albireo Recognizes PFIC Awareness Day 2021
categoriaGlobal News Feed commentoComments Off on Albireo Recognizes PFIC Awareness Day 2021 | dataOctober 5th, 2021
Read All

Genovac Purchases Third Beacon® Optofluidic System and Expands its Capabilities into Cell Line Development

By Dr. Matthew Watson

Genovac Becomes the First Contract Research Organization (CRO) to Leverage the Beacon System for Both Antibody Discovery and Cell Line Development Genovac Becomes the First Contract Research Organization (CRO) to Leverage the Beacon System for Both Antibody Discovery and Cell Line Development

Here is the original post:
Genovac Purchases Third Beacon® Optofluidic System and Expands its Capabilities into Cell Line Development

To Read More: Genovac Purchases Third Beacon® Optofluidic System and Expands its Capabilities into Cell Line Development
categoriaGlobal News Feed commentoComments Off on Genovac Purchases Third Beacon® Optofluidic System and Expands its Capabilities into Cell Line Development | dataOctober 5th, 2021
Read All

Celsion Corporation Adds Key Resources to its Vaccine Development Initiative and Clinical Trial Capabilities

By Dr. Matthew Watson

LAWRENCEVILLE, N.J., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announces the strengthening of its management team with a new hire and a promotion in its vaccine development program, and the hiring of a veteran clinical trial project manager for its Phase II GEN-1 immunotherapy study in advanced ovarian cancer. These changes all are effective immediately and are as follows:

See the original post:
Celsion Corporation Adds Key Resources to its Vaccine Development Initiative and Clinical Trial Capabilities

To Read More: Celsion Corporation Adds Key Resources to its Vaccine Development Initiative and Clinical Trial Capabilities
categoriaGlobal News Feed commentoComments Off on Celsion Corporation Adds Key Resources to its Vaccine Development Initiative and Clinical Trial Capabilities | dataOctober 5th, 2021
Read All

Scopus BioPharma to Present at the LD Micro Main Event

By Dr. Matthew Watson

Scopus to present on the recent launch of Duet Therapeutics, its wholly-owned subsidiary focused on immuno-oncology

Read more:
Scopus BioPharma to Present at the LD Micro Main Event

To Read More: Scopus BioPharma to Present at the LD Micro Main Event
categoriaGlobal News Feed commentoComments Off on Scopus BioPharma to Present at the LD Micro Main Event | dataOctober 5th, 2021
Read All

TCR² Therapeutics Presents Preclinical Data on IL-15 Enhanced TRuCs at AACR Virtual Special Conference on Tumor Immunology & Immunotherapy

By Dr. Matthew Watson

CAMBRIDGE, Mass., Oct. 05, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced the e-poster presentation of new preclinical data at the American Association for Cancer Research (AACR) Virtual Special Conference on Tumor Immunology and Immunotherapy, taking place October 5-6, 2021. The e-poster titled “Expression of an IL-15 Receptor Fusion Protein Enhances the Persistence of TRuC-T Cells” highlights preclinical data on the Company’s proprietary mesothelin-directed T Cell Receptor Fusion Construct (TRuC®) T cells that express IL-15-based enhancements as a strategy for improving T cell persistence. The co-expression of these IL-15 enhancements enriched for naïve and central memory T cells, upregulated the stemness-associated transcription factor TCF-1 and increased TRuC-T cell proliferation upon repeated stimulation with mesothelin-expressing cancer cell lines. In addition, IL-15 promoted the survival of TRuC-T cells in the absence of T cell receptor (TCR) or exogenous cytokine stimulation. In a mesothelioma xenograft mouse model, IL-15 co-expression resulted in a higher number of TRuC-T cells in the tumor and significantly increased their persistence in peripheral blood. The administration of a single dose of IL-15 enhanced TRuC-T cells cleared tumors in all mice and fully protected them from tumor rechallenge.

See more here:
TCR² Therapeutics Presents Preclinical Data on IL-15 Enhanced TRuCs at AACR Virtual Special Conference on Tumor Immunology & Immunotherapy

To Read More: TCR² Therapeutics Presents Preclinical Data on IL-15 Enhanced TRuCs at AACR Virtual Special Conference on Tumor Immunology & Immunotherapy
categoriaGlobal News Feed commentoComments Off on TCR² Therapeutics Presents Preclinical Data on IL-15 Enhanced TRuCs at AACR Virtual Special Conference on Tumor Immunology & Immunotherapy | dataOctober 5th, 2021
Read All

CohBar to Present at H.C. Wainwright 5th Annual NASH Investor Conference

By Dr. Matthew Watson

MENLO PARK, Calif., Oct. 05, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Dr. Joseph Sarret, will present a company overview at the H.C. Wainwright 5th Annual NASH Investor Conference, being held virtually on October 12, 2021.

Read more:
CohBar to Present at H.C. Wainwright 5th Annual NASH Investor Conference

To Read More: CohBar to Present at H.C. Wainwright 5th Annual NASH Investor Conference
categoriaGlobal News Feed commentoComments Off on CohBar to Present at H.C. Wainwright 5th Annual NASH Investor Conference | dataOctober 5th, 2021
Read All

Weblink Instructions for the Annual Meeting of Shareholders of Zivo Bioscience, Inc.

By Dr. Matthew Watson

KEEGO HARBOR, Mich., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Zivo Bioscience, Inc. (NASDAQ: ZIVO, ZIVOW) (“ZIVO” and the “Company”), a biotech/agtech R&D company engaged in the development and commercialization of therapeutic, medicinal and nutritional product candidates originally derived from proprietary algal cultures, today issues a notice to its shareholders concerning the annual shareholder meeting.

Continued here:
Weblink Instructions for the Annual Meeting of Shareholders of Zivo Bioscience, Inc.

To Read More: Weblink Instructions for the Annual Meeting of Shareholders of Zivo Bioscience, Inc.
categoriaGlobal News Feed commentoComments Off on Weblink Instructions for the Annual Meeting of Shareholders of Zivo Bioscience, Inc. | dataOctober 5th, 2021
Read All

Levitee Labs Publishes First Revenue Figures for August 2021

By Dr. Matthew Watson

VANCOUVER, British Columbia, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Levitee Labs Inc. (the "Company" or "Levitee Labs”) (CSE: LVT), an integrative wellness company with a diversified portfolio of healthcare and wellness assets, is pleased to publish revenue figures for the month of August 2021. On a consolidated basis, the Company has recorded (unaudited) revenue of $893,863 for the month of August.

Go here to see the original:
Levitee Labs Publishes First Revenue Figures for August 2021

To Read More: Levitee Labs Publishes First Revenue Figures for August 2021
categoriaGlobal News Feed commentoComments Off on Levitee Labs Publishes First Revenue Figures for August 2021 | dataOctober 5th, 2021
Read All

AXIM® Biotechnologies Appoints Senior DED Expert Dr. Laura Periman to its Medical Advisory Board

By Dr. Matthew Watson

Dr. Periman Joins Chairman Joseph Tauber as Advisory Board’s Second Member Dr. Periman Joins Chairman Joseph Tauber as Advisory Board’s Second Member

More here:
AXIM® Biotechnologies Appoints Senior DED Expert Dr. Laura Periman to its Medical Advisory Board

To Read More: AXIM® Biotechnologies Appoints Senior DED Expert Dr. Laura Periman to its Medical Advisory Board
categoriaGlobal News Feed commentoComments Off on AXIM® Biotechnologies Appoints Senior DED Expert Dr. Laura Periman to its Medical Advisory Board | dataOctober 5th, 2021
Read All

SEngine Precision Medicine and Gustave Roussy Announce Plan to Launch PARIS® Test in Europe

By Dr. Matthew Watson

Prospective joint venture will accelerate precision medicine in Europe by harnessing innovations in high-throughput drug testing, 3D tumor cell culture, and AI analytics established at SEngine Precision Medicine to identify the best personalized therapeutic matches for patients Prospective joint venture will accelerate precision medicine in Europe by harnessing innovations in high-throughput drug testing, 3D tumor cell culture, and AI analytics established at SEngine Precision Medicine to identify the best personalized therapeutic matches for patients

Here is the original post:
SEngine Precision Medicine and Gustave Roussy Announce Plan to Launch PARIS® Test in Europe

To Read More: SEngine Precision Medicine and Gustave Roussy Announce Plan to Launch PARIS® Test in Europe
categoriaGlobal News Feed commentoComments Off on SEngine Precision Medicine and Gustave Roussy Announce Plan to Launch PARIS® Test in Europe | dataOctober 5th, 2021
Read All

Strongbridge Biopharma plc Announces Completion of Acquisition by Xeris Pharmaceuticals, Inc.

By Dr. Matthew Watson

DUBLIN, Ireland and TREVOSE, Pa., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ: SBBP) (the “Company” or “Strongbridge”) today announced that the High Court of Ireland (the "Court") has approved the previously announced proposed acquisition of Strongbridge by Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) (“Xeris”) by means of a scheme of arrangement (the "Scheme") under Chapter 1 of Part 9 of the Irish Companies Act 2014 (the "Act").

More here:
Strongbridge Biopharma plc Announces Completion of Acquisition by Xeris Pharmaceuticals, Inc.

To Read More: Strongbridge Biopharma plc Announces Completion of Acquisition by Xeris Pharmaceuticals, Inc.
categoriaGlobal News Feed commentoComments Off on Strongbridge Biopharma plc Announces Completion of Acquisition by Xeris Pharmaceuticals, Inc. | dataOctober 5th, 2021
Read All

Terns Pharmaceuticals to Present at H.C. Wainwright 5th Annual NASH Investor Conference

By Dr. Matthew Watson

FOSTER CITY, Calif., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases, today announced that management will be presenting at the H.C. Wainwright 5th Annual NASH Investor Conference on Tuesday, October 12 at 2:30 p.m. ET.

Read more from the original source:
Terns Pharmaceuticals to Present at H.C. Wainwright 5th Annual NASH Investor Conference

To Read More: Terns Pharmaceuticals to Present at H.C. Wainwright 5th Annual NASH Investor Conference
categoriaGlobal News Feed commentoComments Off on Terns Pharmaceuticals to Present at H.C. Wainwright 5th Annual NASH Investor Conference | dataOctober 5th, 2021
Read All

CRISPR Therapeutics to Host Virtual Event Highlighting CTX110™ Clinical Data

By Dr. Matthew Watson

-Management to host conference call and webcast on October 12th at 4:30 p.m. ET-

Read more:
CRISPR Therapeutics to Host Virtual Event Highlighting CTX110™ Clinical Data

To Read More: CRISPR Therapeutics to Host Virtual Event Highlighting CTX110™ Clinical Data
categoriaGlobal News Feed commentoComments Off on CRISPR Therapeutics to Host Virtual Event Highlighting CTX110™ Clinical Data | dataOctober 5th, 2021
Read All

Shockwave Medical to Report Third Quarter 2021 Financial Results on November 8, 2021

By Dr. Matthew Watson

SANTA CLARA, Calif., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today announced it will report financial results for the third quarter 2021 after market close on Monday, November 8, 2021. Company management will host a corresponding conference call beginning at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time.

Read the original post:
Shockwave Medical to Report Third Quarter 2021 Financial Results on November 8, 2021

To Read More: Shockwave Medical to Report Third Quarter 2021 Financial Results on November 8, 2021
categoriaGlobal News Feed commentoComments Off on Shockwave Medical to Report Third Quarter 2021 Financial Results on November 8, 2021 | dataOctober 5th, 2021
Read All

Eledon Pharmaceuticals Announces Upcoming Presentation on AT-1501 at the Virtual 2021 International Pancreas and Islet Transplantation Association…

By Dr. Matthew Watson

IRVINE, Calif., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (ALS), announced an upcoming presentation on AT-1501, its lead clinical candidate, at the International Pancreas and Islet Transplantation Association (IPITA) Congress, which is being held virtually from October 20-23, 2021.  An oral presentation on the use of AT -1501, and pre-clinical data showing the effectiveness of AT-1501 in preventing islet allograft rejection in nonhuman primate models, will be featured.

Read the original here:
Eledon Pharmaceuticals Announces Upcoming Presentation on AT-1501 at the Virtual 2021 International Pancreas and Islet Transplantation Association...

To Read More: Eledon Pharmaceuticals Announces Upcoming Presentation on AT-1501 at the Virtual 2021 International Pancreas and Islet Transplantation Association…
categoriaGlobal News Feed commentoComments Off on Eledon Pharmaceuticals Announces Upcoming Presentation on AT-1501 at the Virtual 2021 International Pancreas and Islet Transplantation Association… | dataOctober 5th, 2021
Read All

Neuronetics Announces Commercial Agreement with Success TMS

By Dr. Matthew Watson

MALVERN, Pa., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced a commercial agreement with Success TMS in which Success TMS will exclusively utilize Neuronetics’ platform, NeuroStar Advanced Therapy for Mental Health, for the treatment of patients suffering from treatment-resistant major depressive disorder (MDD). In connection with the commercial agreement, the Company has made a strategic investment in Success TMS in the form of a $10 million term loan to further accelerate the growth of Success TMS’ business.

Excerpt from:
Neuronetics Announces Commercial Agreement with Success TMS

To Read More: Neuronetics Announces Commercial Agreement with Success TMS
categoriaGlobal News Feed commentoComments Off on Neuronetics Announces Commercial Agreement with Success TMS | dataOctober 5th, 2021
Read All

Oncternal Therapeutics Announced Pre-Clinical Data from ONCT-534, an Androgen Receptor N-Terminal-Domain-Binding Small Molecule Degrader, Was Accepted…

By Dr. Matthew Watson

SAN DIEGO, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced pre-clinical data from ONCT-534, an androgen receptor N-terminal-domain-binding small molecule degrader, was accepted for virtual poster presentation at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics on October 7-10, 2021. Oncternal has conducted a series of preclinical studies in collaboration with the Center for Cancer Research at the University of Tennessee Health Science Center.

Read more here:
Oncternal Therapeutics Announced Pre-Clinical Data from ONCT-534, an Androgen Receptor N-Terminal-Domain-Binding Small Molecule Degrader, Was Accepted...

To Read More: Oncternal Therapeutics Announced Pre-Clinical Data from ONCT-534, an Androgen Receptor N-Terminal-Domain-Binding Small Molecule Degrader, Was Accepted…
categoriaGlobal News Feed commentoComments Off on Oncternal Therapeutics Announced Pre-Clinical Data from ONCT-534, an Androgen Receptor N-Terminal-Domain-Binding Small Molecule Degrader, Was Accepted… | dataOctober 5th, 2021
Read All

Surrozen Presented Data Supporting Potential of SZN-1326 at the 2021 United European Gastroenterology Week

By Dr. Matthew Watson

Encouraging preclinical data support continued advancement of SZN-1326 towards first in human clinical studies in 2022 Encouraging preclinical data support continued advancement of SZN-1326 towards first in human clinical studies in 2022

More:
Surrozen Presented Data Supporting Potential of SZN-1326 at the 2021 United European Gastroenterology Week

To Read More: Surrozen Presented Data Supporting Potential of SZN-1326 at the 2021 United European Gastroenterology Week
categoriaGlobal News Feed commentoComments Off on Surrozen Presented Data Supporting Potential of SZN-1326 at the 2021 United European Gastroenterology Week | dataOctober 5th, 2021
Read All

Page 21234..1020..»